The inhomogenity calculated from the ROI-2 performed better than that from the ROI-1, although the diagnostic performance of the other parameters obtained from the two methods showed no statistically significant differences, which reveals that extracting cystic and necrotic portions from the entire tumor lesions is better for evaluating the difference of the intratumoral heterogeneity and more helpful to classify IDH-wild tumors in the lower-grade gliomas. This evidence concerns the gene IDH1 and central nervous system cancer.